LT3204494T - Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai - Google Patents

Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai

Info

Publication number
LT3204494T
LT3204494T LTEP15831237.1T LT15831237T LT3204494T LT 3204494 T LT3204494 T LT 3204494T LT 15831237 T LT15831237 T LT 15831237T LT 3204494 T LT3204494 T LT 3204494T
Authority
LT
Lithuania
Prior art keywords
improved methods
adjuvant adsorption
poliovirus
inactivation
poliovirus inactivation
Prior art date
Application number
LTEP15831237.1T
Other languages
English (en)
Inventor
Rajeev Mhalasakant DHERE
Sambhaji Shankar PISAL
Jagdish Kamalaji ZADE
Rajendra Narayan SABALE
Original Assignee
Serum Institute Of India Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Private Limited filed Critical Serum Institute Of India Private Limited
Publication of LT3204494T publication Critical patent/LT3204494T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/06Inactivation or attenuation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32661Methods of inactivation or attenuation
    • C12N2770/32663Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32671Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP15831237.1T 2014-10-07 2015-10-06 Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai LT3204494T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Publications (1)

Publication Number Publication Date
LT3204494T true LT3204494T (lt) 2020-07-10

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15831237.1T LT3204494T (lt) 2014-10-07 2015-10-06 Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai

Country Status (24)

Country Link
US (1) US10485862B2 (lt)
EP (2) EP3663396A1 (lt)
JP (2) JP6755243B2 (lt)
KR (2) KR102510744B1 (lt)
CN (2) CN113368227A (lt)
AU (2) AU2015334495B2 (lt)
BR (1) BR112017007089A2 (lt)
CA (1) CA2963897C (lt)
CU (1) CU24510B1 (lt)
CY (1) CY1123078T1 (lt)
DK (1) DK3204494T3 (lt)
EA (1) EA201700187A1 (lt)
ES (1) ES2803578T3 (lt)
HU (1) HUE049104T2 (lt)
LT (1) LT3204494T (lt)
MX (1) MX2017004534A (lt)
PE (1) PE20171132A1 (lt)
PH (1) PH12017500627A1 (lt)
PL (1) PL3204494T3 (lt)
PT (1) PT3204494T (lt)
SG (2) SG10202010814RA (lt)
SI (1) SI3204494T1 (lt)
UA (1) UA125788C2 (lt)
WO (1) WO2016063291A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202010814RA (en) * 2014-10-07 2020-12-30 Serum Institute Of India Pvt Ltd Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
EP3454895B1 (en) * 2016-05-10 2024-03-27 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
CA3032901A1 (en) * 2016-08-26 2018-03-01 Serum Institute Of India Private Limited Multivalent vaccine composition
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
CN111526885A (zh) 2017-11-03 2020-08-11 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
JP2021505549A (ja) 2017-11-30 2021-02-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカワクチン及び免疫原性組成物、ならびにその使用方法
US11911457B2 (en) 2018-02-07 2024-02-27 Bharat Biotech International Limited Process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194531C2 (ru) * 1996-07-02 2002-12-20 Коннот Лабораториз Лимитед Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины
WO2007007344A1 (en) * 2004-08-27 2007-01-18 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
BRPI0716518B8 (pt) * 2006-09-07 2021-05-25 Glaxosmithkline Biologicals Sa vacina de ipv e uso da mesma
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2011074006A2 (en) 2009-12-16 2011-06-23 Serum Institute Of India Ltd. Vaccine composition
KR20140026392A (ko) * 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
SG10202010814RA (en) * 2014-10-07 2020-12-30 Serum Institute Of India Pvt Ltd Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Also Published As

Publication number Publication date
EP3204494B1 (en) 2020-04-01
JP6755243B2 (ja) 2020-09-16
KR20210021148A (ko) 2021-02-24
PE20171132A1 (es) 2017-08-09
AU2021269395B2 (en) 2024-05-23
US20170348411A1 (en) 2017-12-07
SG11201702838SA (en) 2017-05-30
CN106999569A (zh) 2017-08-01
PH12017500627A1 (en) 2017-09-25
HUE049104T2 (hu) 2020-08-28
SG10202010814RA (en) 2020-12-30
JP2020203906A (ja) 2020-12-24
SI3204494T1 (sl) 2020-08-31
KR102219638B1 (ko) 2021-02-23
KR20170063947A (ko) 2017-06-08
ES2803578T3 (es) 2021-01-28
JP7063957B2 (ja) 2022-05-09
EP3663396A1 (en) 2020-06-10
UA125788C2 (uk) 2022-06-08
NZ731341A (en) 2023-11-24
CN106999569B (zh) 2021-06-29
CA2963897C (en) 2023-08-22
JP2017533899A (ja) 2017-11-16
AU2015334495A1 (en) 2017-05-25
AU2021269395A1 (en) 2021-12-16
PL3204494T3 (pl) 2020-09-21
CA2963897A1 (en) 2016-04-28
MX2017004534A (es) 2017-10-11
CN113368227A (zh) 2021-09-10
AU2015334495B2 (en) 2021-08-19
EA201700187A1 (ru) 2017-12-29
BR112017007089A2 (pt) 2017-12-26
EP3204494A1 (en) 2017-08-16
DK3204494T3 (da) 2020-07-06
WO2016063291A1 (en) 2016-04-28
US10485862B2 (en) 2019-11-26
KR102510744B1 (ko) 2023-03-15
CY1123078T1 (el) 2021-10-29
PT3204494T (pt) 2020-07-10
CU20170044A7 (es) 2018-09-05
CU24510B1 (es) 2021-05-12

Similar Documents

Publication Publication Date Title
PL3183349T3 (pl) Sposób przygotowania Rebaudiozydu I
SG11201700477WA (en) Microporous carbon adsorbent from natural carbohydrates
LT3204494T (lt) Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai
GB201413335D0 (en) Agricultural methods
LT3113797T (lt) Antikūnai, panaudojimai ir būdai
IL273265A (en) New combinations for antigen-based therapy
PL3197890T3 (pl) Dipodstawione związki diaryloksybenzoheterodiazolowe
HK1249014A1 (zh) 具有作為佐劑的cd40配體的疫苗
EP3154922A4 (en) Process for preparing dialkylbiphenyl isomer mixtures
PL3178803T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
HUE054626T2 (hu) Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
PL3122717T3 (pl) Eteroaminy na bazie 1,2-dialkoholi
AU358414S (en) Frame for chair
GB2522989B (en) Sorbent for halogen compounds
ZA201607068B (en) Methods for treating hypersomnia
HRP20181756T1 (hr) Režim liječenja sa spojem tiakumicina
GB201406755D0 (en) Indigestion, angled adjustable bed
HU4547U (en) Bed for pregnants
GB201420970D0 (en) eGURE, egure, Egure
AU2014905272A0 (en) Improved bed
GB201405427D0 (en) Disc Cultivator
GB201413337D0 (en) Agricultural methods
TWM488919U (en) Storagable bed frame
GB201413950D0 (en) Antibodies, uses & methods
GB201400597D0 (en) Antibodies, uses & methods